-
1Report
Subject Terms: иммунная система, immune system, side effects, ингибиторы иммунных контрольных точек, иммуноопосредованные нежелательные реакции, противоопухолевая терапия, побочные эффекты, immune-mediated adverse reactions, immune checkpoints, immune checkpoint inhibitors, иммунные контрольные точки, antitumor therapy
-
2Academic Journal
Authors: M. Yu. Fedyanin, A. V. Snegovoy, V. V. Breder, Yu. N. Linkova, A. V. Zinkina-Orikhan, S. B. Setkina, S. N. Fogt, V. S. Chistiakov, N. A. Kravtsova, М. Ю. Федянин, А. В. Снеговой, В. В. Бредер, Ю. Н. Линькова, А. В. Зинкина-Орихан, С. Б. Сеткина, С. Н. Фогт, В. С. Чистяков, Н. А. Кравцова
Contributors: The study sponsor is BIOCAD JSC (Russia)., Спонсор исследования — AO «БИОКАД» (Россия).
Source: Safety and Risk of Pharmacotherapy; Том 11, № 2 (2023); 215-230 ; Безопасность и риск фармакотерапии; Том 11, № 2 (2023); 215-230 ; 2619-1164 ; 2312-7821
Subject Terms: клинические исследования, pembrolizumab, biosimilar, PD-1 inhibitor, immune-related adverse events, immune-mediated adverse reactions, immune-checkpoint inhibitors, immunotherapy, clinical trials, пембролизумаб, биоаналог, PD-1-ингибитор, иммуноопосредованные нежелательные явления, иммуноопосредованные нежелательные реакции, ингибиторы иммунных контрольных точек, иммунотерапия
File Description: application/pdf
Relation: https://www.risksafety.ru/jour/article/view/360/737; https://www.risksafety.ru/jour/article/view/360/788; https://www.risksafety.ru/jour/article/downloadSuppFile/360/347; Stege H, Haist M, Nikfarjam U, Schultheis M, Heinz J, Pemler S, et al. The status of adjuvant and neoadjuvant melanoma therapy, new developments and upcoming challenges. Target Oncol. 2021;16(5):537–52. https://doi.org/10.1007/s11523-021-00840-3; Qiu Z, Chen Z, Zhang C, Zhong W. Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. Exp Hematol Oncol. 2019;8:19. https://doi.org/10.1186/s40164-019-0143-z; Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M, et al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers (Basel). 2021;13(1):131. https://doi.org/10.3390/cancers13010131; Márquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, González-Cao M, Martín-Algarra S. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med. 2015;3(18):267. PMID: 26605313; Feng MY, Chan LL, Chan SL. Drug treatment for advanced hepatocellular carcinoma: first-line and beyond. Curr Oncol. 2022;29(8):5489–507. https://doi.org/10.3390/curroncol29080434; Resch I, Bruchbacher A, Franke J, Fajkovic H, Remzi M, Shariat SF, et al. Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines. ESMO Open. 2021;6(4):100122. https://doi.org/10.1016/j.esmoop.2021.100122; Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–8. https://doi.org/10.1001/jamaoncol.2018.3923; El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017;119:1–12. https://doi.org/10.1016/j.critrevonc.2017.09.002; Vaddepally R, Doddamani R, Sodavarapu S, Madam NR, Katkar R, Kutadi AP, et al. Review of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC)—their incidence, management, multi-organ irAEs, and rechallenge. Biomedicines. 2022;10(4):790. https://doi.org/10.3390/biomedicines10040790; Olsen TA, Zhuang TZ, Caulfield S, Martini DJ, Brown JT, Carthon BC, et al. Advances in knowledge and management of immune-related adverse events in cancer immunotherapy. Front Endocrinol (Lausanne). 2022;13:779915. https://doi.org/10.3389/fendo.2022.779915; Allouchery M, Beuvon C, Pérault-Pochat MC, Roblot P, Puyade M, Martin M. Safety of immune check-point inhibitor resumption after interruption for immune-related adverse events, a narrative review. Cancers (Basel). 2022;14(4):955. https://doi.org/10.3390/cancers14040955; Kubo T, Hirohashi Y, Tsukahara T, Kanaseki T, Murata K, Morita R, Torigoe T. Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy. Immunol Med. 2022;45(2):108–18. https://doi.org/10.1080/25785826.2021.1976942; Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;17(8):504–15. https://doi.org/10.1038/s41571-020-0352-8; Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest. 2018;128(2):715–20. https://doi.org/10.1172/JCI96798; Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H, et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci. 2018;109(11):3583–90. https://doi.org/10.1111/cas.13800; Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer. 2017;123(S11):2143–53. https://doi.org/10.1002/cncr.30444; Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66(5):581–92. https://doi.org/10.1007/s00262-017-1962-6; Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45. https://doi.org/10.1126/scitranslmed.3008002; Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. https://doi.org/10.1038/s41572-020-0160-6; Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391. https://doi.org/10.1038/ncomms10391; Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol. 2011;18(13):3579–85. https://doi.org/10.1245/s10434-011-1976-9; Valpione S, Pasquali S, Campana LG, Piccin L, Mocellin S, Pigozzo J, Chiarion-Sileni V. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. J Transl Med. 2018;16(1):94. https://doi.org/10.1186/s12967-018-1467-x; Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol Immunother. 2019;68(6):917–26. https://doi.org/10.1007/s00262-019-02321-z; Solomon B, Young RJ, Rischin D. Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 2018;52(Pt 2):228–40. https://doi.org/10.1016/j.semcancer.2018.01.008; Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583–9. https://doi.org/10.1093/annonc/mdw640; Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol. 2019;5(3):376–83. https://doi.org/10.1001/jamaoncol.2018.5860; Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89(11):1127–34. https://doi.org/10.1212/WNL.0000000000004359; Clavel T, Gomes-Neto JC, Lagkouvardos I, Ramer-Tait AE. Deciphering interactions between the gut microbiota and the immune system via microbial cultivation and minimal microbiomes. Immunol Rev. 2017;279(1):8–22. https://doi.org/10.1111/imr.12578; Cappelli LC, Dorak MT, Bettinotti MP, Bingham CO, Shah AA. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology (Oxford). 2019;58(3):476–80. https://doi.org/10.1093/rheumatology/key358; Hasan Ali O, Berner F, Bomze D, Fässler M, Diem S, Cozzio A, et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer. 2019;107:8–14. https://doi.org/10.1016/j.ejca.2018.11.009; Fountzilas E, Lampaki S, Koliou GA, Koumarianou A, Levva S, Vagionas A, et al. Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. Cancer Immunol Immunother. 2022;71(2):327–37. https://doi.org/10.1007/s00262-021-02985-6; Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018;91:21–9. https://doi.org/10.1016/j.ejca.2017.12.008; Robert C, Hwu WJ, Hamid O, Ribas A, Weber JS, Daud AI, et al. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma. Eur J Cancer. 2021;144:182–91. https://doi.org/10.1016/j.ejca.2020.11.010; Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, et al. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy. Int J Radiat Oncol Biol Phys. 2017;98(2):344–51. https://doi.org/10.1016/j.ijrobp.2017.02.003; Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368(14):1365–6. https://doi.org/10.1056/NEJMc1302338; Vizcarrondo FR, Patel SP, Pennell NA, Pakkala S, West H, Kratzke R, et al., Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 2016;27(Suppl 6):vi416–54. https://doi.org/10.1093/annonc/mdw383.91; Ahn M-J, Yang J, Yu H, Saka H, Ramalingam S, Goto K, et al. 136O: osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. Journal of Thoracic Oncology. 2016;11(4):S115. https://doi.org/10.1016/S1556-0864(16)30246-5; Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019;14(12):1692–700. https://doi.org/10.2215/CJN.00990119; Raghavan R, Shawar S. Mechanisms of drug-induced interstitial nephritis. Adv Chronic Kidney Dis. 2017;24(2):64–71. https://doi.org/10.1053/j.ackd.2016.11.004; Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AP, Okhuysen PC, et al. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer. 2019;7(1):242. https://doi.org/10.1186/s40425-019-0714-x; Проценко СА, Антимоник НЮ, Берштейн Л.М, Жукова НВ, Новик АВ, Носов ДА и др. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями. Злокачественные опухоли. 2022;10(3s2):168–99. https://doi.org/10.18027/2224-5057-2020-10-3s2-50; Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–42. https://doi.org/10.1093/annonc/mdx225; Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021;80(1):36–48. https://doi.org/10.1136/annrheumdis-2020-217139; Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw. 2020;18(3):230–41. https://doi.org/10.6004/jnccn.2020.0012; Ito M, Fujiwara S, Fujimoto D, Mori R, Yoshimura H, Hata A, et al. Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient. Ann Oncol. 2017;28(9):2318–9. https://doi.org/10.1093/annonc/mdx252; Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, et al. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis. Eur J Cancer. 2018;102:49–51. https://doi.org/10.1016/j.ejca.2018.07.125; Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson NA, Miller WH Jr. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N Engl J Med. 2019;380(24):2375–6. https://doi.org/10.1056/NEJMc1903064; Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377–9. https://doi.org/10.1056/NEJMc1901677; Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis. 2017;76(12):2061–4. https://doi.org/10.1136/annrheumdis-2017-211560; Комиссарова ВА. Меры минимизации рисков в фармаконадзоре: обзор отечественного и зарубежного опыта. Качественная клиническая практика. 2019;(3):33–43. https://doi.org/10.24411/2588-0519-2019-10081; Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. https://doi.org/10.1056/NEJMoa1503093; https://www.risksafety.ru/jour/article/view/360
-
3Academic Journal
Authors: E. L. Nasonov, Е. Л. Насонов
Source: Rheumatology Science and Practice; Vol 56, No 1 (2018); 5-9 ; Научно-практическая ревматология; Vol 56, No 1 (2018); 5-9 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20181
Subject Terms: иммуноопосредованные нежелательные реакции (immune related adverse evenеs), programmed death-1 (PD1), immune-mediated adverse reactions (immune related adverse events), рецептор программируемой смерти 1 (programmed death-1 – PD1)
File Description: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/2492/1650; Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-33. doi:10.1172/JCI78088; Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227-42. doi:10.1038/nri3405; Насонов ЕЛ. Абатацепт при ревматоидном артрите: новая форма, новые механизмы, новые возможности. Научно-практическая ревматология. 2015;53(5):522-41 [Nasonov EL. Abatacept for rheumatoid arthritis: A novel formulation, new mechanisms, new possibilities. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):522-41 (In Russ.)]. doi:10.14412/1995-4484-2015-522-541; Buchbinder EI, Desari A. CTLA-4 and PD-1 pathways. Similarities, differences, and implications of their inhibition. Amer J Clin Oncol. 2016;39(1):98-106. doi:10.1097/COC.0000000000000239; Padrol DM. The blockade on immune checkpoints in cancer immunotherapy. Nat Rev Immunol. 2012;12:252-64. doi:10.1038/nrc3239; June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med. 2017 May 5;23(5):540-7. doi:10.1038/nm.4321; Cousin S, Italiano A. Molecular pathways: immune checkpoint antibodies and their toxicities. Clin Cancer Res. 2016;22:4550-5. doi:10.1158/1078-0432.CCR-15-2569; Yoest JM. Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. Immunotargets Ther. 2017;6:73-82. doi:10.2147/ITT.S126227; Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-48. doi:10.1016/j.ejca.2015.11.016; Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of antiPD-1 therapy. Eur J Cancer. 2016;60:210-25. doi:10.1016/j.ejca.2016.02.024; Kostine M, Rouxel L, Barnetche T, et al; FHU ACRONIM. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2017 Nov 16. doi:10.1136/annrheumdis-2017212257; Cappelli LC, Shah AA, Bingham CO 3rd. Immune-Related Adverse Effects of Cancer Immunotherapy – Implications for Rheumatology. Rheum Dis Clin North Am. 2017;43(1):65-78. doi:10.1016/j.rdc.2016.09.007; Cappelli LC, Gutierrez AK, Bingham CO, et al. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res. 2017;69:1751-63. doi:10.1002/acr.23177; Calabrese C, Kirchner E, Kontzias K, et al. Rheumatic immunerelated adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017;3(1):e000412. doi:10.1136/rmdopen-2016-000412; Suarez-Almazor ME, Kim ST, Abdel-Wahab N, et al. Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheum. 2017;69:687-99. doi:10.1002/art.40043; Naidoo J, Cappelli LC, Forde PM, et al. Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade. Oncologist. 2017;22:627-30. doi:10.1634/theoncologist.2016-0390; Rutgers A, van den Brom RRH, Hospers GAP, et al. Systemic vasculitis developed after immune checkpoint inhibition. Arthritis Care Res (Hoboken). 2017 Dec 1. doi:10.1002/acr.23481; Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4. Arthritis Rheum. 2014;66:768-9. doi:10.1002/art.38282; De Velasco G, Bermas B, Choueiri TK. Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheum. 2016;68:556-7. doi:10.1002/art.39406; Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76:43-50. doi:10.1136/annrheumdis-2016-209595; Chan MM, Kefford RF, Carlino M, et al. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother. 2015;38:37-9. doi:10.1097/CJI.0000000000000060; Law-Ping-Man S, Martin A, Briens E, et al. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatology (Oxford). 2016;55:2087-9. doi:10.1093/rheumatology/kew281; Zhang H, Watanabe R, Berry GJ, et al. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A. 2017;114: E970-9. doi:10.1073/pnas.1616848114; Bilen MA, Subudhi SK, Gao J, et al. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer. 2016;4:36. doi:10.1186/s40425-016-0139-8; Belkhir R, Burel SL, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76:1747-50. doi:10.1136/annrheumdis-2017-211216; Bonigen J, Raynaud-Donzel C, Hureaux J, et al. Anti-PD1induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol. 2017;31:e254-7. doi:10.1111/jdv.14011; Garel B, Kramkimel N, Trouvin AP, et al. Pembrolizumabinduced polymyalgia rheumatica in two patients with metastatic melanoma. Joint Bone Spine. 2017;84:233-4. doi:10.1016/j.jbspin.2016.01.007; Lidar M, Giat E, Garelick D, et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018 Jan 13. pii: S1568-9972(18)30010-7. doi:10.1016/j.autrev.2018.01.003; Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346-53. doi:10.1001/jamaoncol.2016.1051; Giat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmun Rev. 2017 July 12. doi:10.1016/j.autrev.2017.07.022; Van der Vlist M, Kuball J, Radstake TR, Meyaard L. Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593604. doi:10.1038/nrrheum.2016.131; Ma W-T, Chang C, Gershwin ME, Lian Z-X. Development of autoantibodies preceded clinical manifestations of autoimmune diseases: a comprehensive review. J Autoimmun. 2017;83:95-112. doi:10.1016/j.jaut.2017.07.003; Kim ST, Tayar J, Trinh VA, et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis. 2017;76(12):2061-4. doi:10.1136/annrheumdis2017-211560; Esfahani K, Miller WH. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med. 2017;376:1989-91. doi:10.1056/NEJMc1703047; Bertrand F, Montfort A, Marcheteau E, et al. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. 2017;8(1):2256. doi:10.1038/s41467-017-02358-7
-
4Report
Subject Terms: immune checkpoint inhibitors, nivolumab, psoriatic arthritis, ниволумаб, ингибиторы иммунных контрольных точек, иммуноопосредованные нежелательные реакции, белок программируемой клеточной гибели 1, immune-related adverse events, псориатический артрит, programmed cell death protein 1, 3. Good health